GlassScriptPhysician profile
Kathryn E Mchugh
NPI 1851771174
$4,855.08
in general payments reported to CMS, 2019-2025
38 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $605 · 2021: $673 · 2022: $949 · 2023: $1,050 · 2024: $577 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $709.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $443.99 | 2021-2025 | |
| Amgen INC. | $432.40 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $358.85 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $321.60 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $319.50 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $313.28 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.48 | 2019-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $214.43 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Abbott Laboratories | $160.78 | 2021-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $146.25 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $139.32 | 2019-2022 | |
| Amarin Pharma, INC. | $117.84 | 2020-2021 | |
| Exact Sciences Corporation | $97.95 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $88.19 | 2020-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Mchugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.